The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial

Rogers, Geraint B.; Bruce, Kenneth D.; Martin, Megan L.; Burr, Lucy; Serisier, David J.

doi:10.1016/s2213-2600(14)70213-9

Cited by 156 publications

(119 citation statements)

References 37 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…There was no detectable difference in P. aeruginosa load between the treatment and placebo groups, consistent with previously reported data [10], and supportive of the fact that erythromycin is not bactericidal to P. aeruginosa. Despite this, erythromycin is relevant to P. aeruginosa physiology, as demonstrated by the significant down-regulation of the key quorum sensing genes lasR and pqsA.…”

Section: Discussionsupporting

confidence: 91%

“…shown to decrease exacerbation rates in non-CF bronchiectasis [7][8][9] and is particularly effective in those colonised with P. aeruginosa, a pathogen considered inherently resistant to macrolide [10].…”

Section: Australian and New Zealand Standard Research Classificationsmentioning

confidence: 99%

“…The demonstration of benefit in non-CF bronchiectasis and CF subjects colonised with P. aeruginosa, an organism where macrolide is neither bacteriostatic nor bactericidal, implies a non-antibiotic mechanism of benefit [10]. Subsequent in vitro data have described a range of anti-inflammatory and immunomodulatory effects and consequently it has been generally assumed that macrolides exert their benefits by modulating the inflammatory phenotypes of these diseases [37,39].…”

Section: Macrolide Antibioticsmentioning

confidence: 99%

“…DNA extraction for both PCR and microbiome analysis were performed on 200 µL portions of paired induced sputum using a combination of physical disruption and a phenol/chloroform-based methodology as described previously [10]. This was completed by A/Professor Geraint Rogers at Kings College, London.…”

Section: Dna Extractionmentioning

confidence: 99%

“…P. aeruginosa levels were determined using a TaqMan assay, in which a 117 bp region between positions 330 to 447 of the P. aeruginosa oprL gene was amplified, as described previously [131]. H. influenzae density was determined using a TaqMan assay, in which a 90-bp region between positions 518 to 608 of the H. influenzae hel gene was amplified [10]. PBMCs were activated with the addition of 25 ng PMA and 250 ng ionomycin per well, and treated with 10 µM 3-oxo-C12-HSL or 10 µM PQS diluted in DMSO (1:10,000 final concentration).…”

Section: Quantitative Pcr For the Determination Of Bacterial Loadmentioning

confidence: 99%

See 4 more Smart Citations

An investigation into the effect of erythromycin on Pseudomonas aeruginosa quorum sensing in non-cystic fibrosis bronchiectasis

Burr¹

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Australian and New Zealand Standard Research Classificationsmentioning

confidence: 99%

Section: Macrolide Antibioticsmentioning

confidence: 99%

Section: Dna Extractionmentioning

confidence: 99%

Section: Quantitative Pcr For the Determination Of Bacterial Loadmentioning

confidence: 99%

See 3 more Smart Citations

An investigation into the effect of erythromycin on Pseudomonas aeruginosa quorum sensing in non-cystic fibrosis bronchiectasis

Burr¹

View full text Add to dashboard Cite

show abstract

Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults

Hnin

Nguyen

Carson‐Chahhoud

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

Interventions for bronchiectasis: an overview of Cochrane systematic reviews

Welsh

Evans

Fowler

et al. 2015

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Bronchiectasis is a chronic respiratory disease characterised by abnormal dilatation of the bronchi, and presents typically with a chronic productive cough (or chronic wet cough in children) and recurrent infective exacerbations. It significantly impacts daily activities and quality of life, and can lead to recurrent hospitalisations, severe lung function impairment, respiratory failure and even death. Objectives To provide an overview of the efficacy and safety of interventions for adults and children with bronchiectasis from Cochrane reviews. To identify gaps in the evidence base that will inform recommendations for new research and reviews, and to summarise information on reported outcomes and make recommendations for the reporting of standard outcomes in future trials and reviews. Methods We included Cochrane reviews of non-cystic fibrosis (CF) bronchiectasis. We searched the Cochrane Database of Systematic Reviews. The search is current to 11 February 2015. We also identified trials that were potentially eligible for, but not currently included in, published reviews to make recommendations for new Cochrane reviews. We assessed the quality of included reviews using the AMSTAR criteria. We presented an evidence synthesis of data from reviews alongside an evidence map of clinical trials and guideline data. The primary outcomes were exacerbations, lung function and quality of life. Main results We included 21 reviews but extracted data from, and rated the quality of, only nine reviews that reported results for people with bronchiectasis alone. Of the reviews with no usable data, two reviews included studies with mixed clinical populations where data were not reported separately for people with bronchiectasis and 10 reviews did not contain any trials. Of the 40 studies included across the nine reviews, three (number of participants nine to 34) included children. The studies ranged from single session to year-long studies. Each review included from one to 11 trials and 28 (70%) trials in the overview included 40 or fewer participants. The total number of participants included in reviews ranged from 40 to 1040. The age range of adult participants was from 36 to 73 years and children Interventions for bronchiectasis: an overview of Cochrane systematic reviews (Review)

show abstract

The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial

Cited by 156 publications

References 37 publications

An investigation into the effect of erythromycin on Pseudomonas aeruginosa quorum sensing in non-cystic fibrosis bronchiectasis

An investigation into the effect of erythromycin on Pseudomonas aeruginosa quorum sensing in non-cystic fibrosis bronchiectasis

Prolonged antibiotics for non-cystic fibrosis bronchiectasis in children and adults

Interventions for bronchiectasis: an overview of Cochrane systematic reviews

Contact Info

Product

Resources

About